New Target for Uveitis Therapy - Summary - MDSpire

New Target for Uveitis Therapy

Could targeting cGAS-STING represent a new treatment avenue for uveitis?

  • May 21, 2026

  • 3 min

Share

Objective:

To explore the role of the cGAS–STING pathway in uveitis and its potential as a therapeutic target.

Key Findings:
  • cGAS–STING pathway is strongly activated in inflamed retinas.
  • Mitochondrial DNA accumulates in the cytoplasm post-LPS exposure, triggering cGAS activation.
  • Cgas knockout mice showed significantly reduced ocular inflammation compared to wild-type mice.
  • Absence of cGAS led to decreased retinal macrophage recruitment and increased regulatory T cells.
Interpretation:

The cGAS–STING pathway is a central driver of inflammation in uveitis, suggesting it could be a novel therapeutic target.

Limitations:
  • Further validation in human tissues is needed.
  • Uncertainty whether STING-dependent mechanisms are solely responsible for the observed effects.
Conclusion:

Targeting the cGAS–STING pathway may provide a new strategy for treating refractory uveitis, pending further research.

Original Source(s)

New Target for Uveitis Therapy

  • May 21, 2026

Related Content

Recognizing MacTel Masquerades

Imaging features such as retinal thinning and ellipsoid zone loss can help differentiate MacTel from AMD and related retinal diseases.

Approaching Uveitic Retinal Detachments

Uveitis Corner: Careful control of inflammation, thoughtful surgical planning, and vigilant postoperative management can help optimize outcomes in these complex cases.

Retinal connections to migraine